NCT02315599
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Enrolling by Invitation
Not specifiedAges 1–99ObservationalNational Cancer Institute (NCI)Government-funded
~500 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:anti-CD19 CAR
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Conduct long term safety evaluations after gene therapy
Measured over Every 3 months X 1 year then annually X 15 years
Conditions
Where it's being run
1 sites across 1 statesMaryland1
Study leadership
- John W Glod, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participants must be identified eligible for, participating in, or have participated in a POB genetically engineered cellular therapy clinical trial and have received/or be scheduled to receive a genetically engineered cellular therapy.
All monitoring and testing described in this protocol will pertain ONLY to genetically engineered cellular therapy received at the National Institutes of Health (NIH). RCR/RCL monitoring and persistence will NOT be followed for cells administered at another institution.
What this trial measures
- Conduct long term safety evaluations after gene therapyEvery 3 months X 1 year then annually X 15 years
PCR results (for RCR/RCL, gene transduced cells)